TVM Capital Life Science

🚀 Discover the Power of AI in Biopharma: TVM Capital Life Science to Host Thought-Provoking Sessions at #BIOEurope2024! Join the discussion on how AI is reshaping drug discovery and development, diagnostics, patient care and more! 🗓️ Save the date: Tuesday, November 5th ⏰ Time: 15:30 - 17:30 📍Location: Room K1 🧠 Featuring top experts from Google Europe, Evotec, Indivumed, and more. https://lnkd.in/eqyKyNr8 #AI #LifeSciences #Innovation #VentureCapital 

🚀 TVM Capital Life Science Spotlight at BIO-Europe 2024: Pioneering AI in Drug Development and Diagnostics 🌍 TVM is pleased to be featured in two insightful articles by independent journalist Cormac Sheridan, published by EBD Group from BIO-Europe 2024. These articles showcase the transformative conversations the @TVM hosted panels sparked around artificial intelligence (AI) in drug development and diagnostics. The panel: "AI in Drug Development: Dreams and Realities," explored both the vast potential and the sober actuality of AI in advancing drug discovery. Key takeaways: - Early failure recognition: AI tools may save time and resources by identifying failure risks earlier. - Human insight still essential: While AI has the potential to accelerate processes, human intelligence remains crucial for interpreting complex biological data. - New paradigms in discovery: From focused screening campaigns to RNA-based biomarkers, AI has the potential to rewrite the rulebook for drug discovery. The article "Biotech Partnering a Constant Amid Industry Uncertainty," spotlighted the power of new technologies, including AI, in drug discovery and development as well as diagnostics. As TVM Managing Partner Hubert Birner highlighted, AI could become an important tool to improve overall success rates for drug development and diagnostics. 💡 At TVM Capital Life Science, we believe AI is not just a tool but, when wielded correctly, has the potential to be a catalyst for better patient care. Read the full articles here: https://lnkd.in/ebddWiZG and https://lnkd.in/exnErAZt #BIOEurope2024 #ArtificialIntelligence #DrugDevelopment #Diagnostics #Innovation #LifeSciences

💡Sind Ideen immer Risiko? 🤔    Frühphasenfinanzierungen sowie Neu- und Ausgründungen in der Biotechnologie sind jüngst rückläufig. Beteiligungskapital, insbesondere Seed- und Venture-Finanzierungen, sind in dieser Schlüsselbranche unerlässlich geworden, damit aus den wissenschaftlichen Ideen von heute, bahnbrechende Therapien von morgen entstehen können. 💸🌱    Als Venture-Capital-Unternehmen investiert TVM Capital Life Science in differenzierte Ansätze, damit Patienten Zugang zu Innovationen erhalten. 🤝 Mit einem verwalteten Volumen von derzeit über 900 Millionen Euro und bis heute insgesamt über 150 Life-Science-Investitionen unterstützt TVM frühphasige Entwicklungsprojekte, aber auch Late-Stage-Technologien, wie Therapeutika, Medizintechnik oder HealthTech, die Patienten in Deutschland und auf der ganzen Welt zugute kommen.  📽 https://lnkd.in/dKKFWW6y   ***  TVM Capital Life Sciences supports the campaign of BVK Bundesverband Beteiligungskapital, the German Private Equity and Venture Capital Association, to raise awareness of the decisive role that venture capital and other equity investments are playing in the economic transformation of Germany. 🌍🚀    #HealthcareInnovations #Healthcare #VentureCapital #LifeSciences #InvestmentStrategy #BVK #Kapitalmarkt

📢 Advocating for Safer Healthcare Environments! 🌍 TVM Capital Life Sciences applauds the AMA’s recent focus on enhancing protection against ionizing radiation exposure in healthcare. With millions of radiation-based procedures performed annually, better PPE is essential—especially for women, who face higher risks of breast cancer due to limited coverage in current gear.   TVM is proud that portfolio company, Egg Medical, is advancing solutions to reduce radiation exposure for healthcare workers 💡. Protecting clinicians’ health means they can better care for others, and EGG Medical is making that possible with the EggNest™, a comprehensive radiation protection system for the entire interventional team - reducing up to 91% of scatter radiation and integrates into the modern cath lab workflow 🔬.   Learn more: https://lnkd.in/ee_zw8jx

🌟 Igniting Healthcare’s Future in the DACH Region 🚀   This week, TVM Capital Life Science, Heal Capital, MedTech Entrepreneurs, and Healthcare Minutes hosted the inaugural Healthcare Minutes Dinner in Munich — an exclusive gathering designed to forge impactful connections across the life sciences ecosystem. Leading investors, top executives from healthcare and pharma, and key experts from scientific institutions came together to discuss advancing healthcare in the DACH region.   By providing a new platform for exchange and collaboration, the event strives to gather leading decision-makers to drive innovation, start joint ventures, and grow strategic partnerships that could benefit the entire healthcare sector. We look forward to building on this momentum in our upcoming editions.   Special thanks to Stefan Fischer, Eckhardt Weber, Dominik Moll, and Leonard Rinser 🤘🏼 for making the event a success. Here’s to jointly shaping the future of healthcare in our region!   #Healthcare #MedTech #Pharma #VC #Investors

🧬 Discover the Power of AI in Biopharma – Exclusive session –  “Why Did It Have to Be Me?”: AI for Diagnosis AI is reshaping diagnostics! Discover how enhanced digital technologies are improving accuracy and efficiency in medical diagnostics in this session at #BIOEurope2024. 📅 Date: Tuesday, November 5th ⏰ Time: 16:45 - 17:30 📍Location: Room K1 🧑🏫 Moderator: Bora Erdemli, Partner at ZS Speakers include: Ralf Huss (BioM), David Krummen (Vektor Medical, Inc.), Andrea Gisle Joosen (Zühlke Group), Miha Stajdohar (Genialis) and Andrea Riposati (Dante Labs). #AIDiagnostics #BIOEurope2024 #AIforHealthcare #PrecisionMedicine #VentureCapital

🔍 Discover the Power of AI in Biopharma – Exclusive session – “I Have a Dream”: AI for Drug Discovery Imagine AI discovering life-saving drugs faster than ever. This session at #BIOEurope2024 will showcase cutting-edge advancements in AI for drug discovery, featuring industry pioneers. 📅 Date: Tuesday, November 5th ⏰ Time: 16:00 - 16:45 📍Location: Room K1 🧑🏫 Moderator: Maria Luisa Pineda, PhD., Vice Chair, Cofounder and Board Member of Envisagenics Don’t miss insights from experts like Rogier Rooswinkel (Forbion), Prof. Dr. Hartmut Juhl (Indivumed Therapeutics), Lovisa Afzelius (Flagship Pioneering), Tim James (Evotec), Michelle Chen (Insilico Medicine), Stephan Brock (Molecular Health) and Nikolaus Krall (Exscientia)! https://lnkd.in/eqyKyNr8 #AIforDrugDiscovery #BIOEurope2024 #HealthcareInnovation #Biopharma #VentureCapital

💡 Discover the Power of AI in Biopharma – Exclusive session –  “Indestructible”: Why AI is Crucial for the Future of Biopharma AI isn't just a trend—it is having a  transformative impact on healthcare and biopharma.💡 Hear from Verena Schustereder of Google Europe in this keynote session at #BIOEurope2024 as she explains why AI is set to revolutionize the industry. 📅 Date: Tuesday, November 5th ⏰ Time: 15:30 - 16:00 📍Location: Room K1 🧑🏫 Moderators: Hubert Birner, Managing Partner at TVM Capital Life Science and Denis Dubuy, Director of Corporate Development at Owkin Don’t miss this deep dive session! #AI #LifeSciences #Innovation #VentureCapital

🧬 Honored to return to BIOTECH AUSTRIA, the emerging platform for the local biotech industry, and proud to contribute to its ongoing success. Congratulations to the organizers for the incredible progress made in just two years! 🧬 With over 250 participants from 13 countries, this year’s summit in Innsbruck not only solidified its role as a key event for the Austrian biotech scene but also fostered high-level yet personal exchanges among leading investors, scientists, and start-ups. TVM Capital Life Science looks forward to continuing the conversation next October 2025 in Graz! Check out transkript's recap of the second Biotech Summit Austria and the exciting discussions it sparked across the industry. https://lnkd.in/d7C5Pymu #BiotechAustria #Innovation #LifeSciences #Collaboration

🚀 Perspectives on the German Biotech Funding landscape 🚀   In his recent article, TVM Capital Life Sciences' Managing Partner, Hubert Birner, highlights the resilience of the German biotech sector amidst challenging times. While the past few years have tested the industry with economic and geopolitical headwinds, 2024 is showing signs of a positive shift when it comes to accessing capital.   Key takeaways: 💼 Capital is on the Rise: German biotech firms raised €1.1B in 2023—an increase from 2022—with early 2024 already seeing nearly €500M in private investments. 🌍 Global Interest: Many German companies have successfully attracted significant foreign investments, underscoring their global competitiveness. 🤝 Opportunities & Challenges: Despite encouraging trends, challenges remain, including a decline in new company formations and early-stage funding.   Hubert calls for continued collaboration to ensure Germany remains an attractive hub for biotech innovation.   Read the full article in German here: https://lnkd.in/gbY3sPkJ   #biotechnology #lifeSciences #innovation #investment #GermanBiotech #TVM